New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 4, 2012
12:41 EDTQGENQIAGEN reaffirms FY12 EPS view $1.04-1.06, consensus $1.00
Sees revenue up approximately 8-9% CER on a mix of contributions from the acquisitions of Cellestis and Ipsogen in 2011 and AmniSure in May 2012, as well as growth in the rest of the business. Full-year reported sales are expected to be adversely affected by currency movements against the U.S. dollar, QIAGEN's reporting currency.This guidance takes into account approximately half a cent of dilution expected on adjusted EPS results in the fourth quarter of 2012 from the combined effect of the share repurchase program as well as higher interest expenses incurred through the U.S. private placement. These expectations do not take into account any further acquisitions that could be completed in 2012.
News For QGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 12, 2015
09:31 EDTQGENTokai Pharmaceuticals announces collaboration with QIAGEN
Subscribe for More Information
05:36 EDTQGENQIAGEN announces regulatory registration of lung cancer companion diagnostic
Subscribe for More Information
January 11, 2015
15:20 EDTQGENQIAGEN expects to meet 2014 guidance ex-charges
Subscribe for More Information
15:16 EDTQGENQIAGEN to take Q4 charges of $41M for acquisition, restructuring
QIAGEN said that following its acquisition of the Enzyme Solutions Unit from Enzymatics, it will take a business integration and acquisition-related pre-tax charge on operating income in Q4 of approximately $21M, or 6c per share of adjusted diluted EPS, and of which $18M are non-cash items. These charges, which will be excluded from adjusted results, involve actions to reduce overlapping activities and sites, including the closing of the Gaithersburg, Maryland, site. In addition, following a review to further improve efficiency and effectiveness, QIAGEN will now take a restructuring-related pre-tax charge on operating income in Q4 of approximately $26M, or 8 per share, of which $20M are non-cash items. In line with QIAGEN's policy, the restructuring charges, which primarily involve the impairment of various technology-related assets, will not be excluded from adjusted results.
15:12 EDTQGENQIAGEN acquires Enzyme Solutions Unit of Enzymatics
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use